300149.SZ
睿智医药
SZSE · M 科研服务 · CN
CNY 9.70
−6.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.1B | 970.2M | 1.1B | 1.3B |
| Cost of Revenue | 828.1M | 810.0M | 758.7M | 843.1M | 989.3M |
| Gross Profit | 312.1M | 324.7M | 211.5M | 295.2M | 337.3M |
| Operating Expenses | |||||
| R&D Expense | 63.3M | 59.8M | 59.6M | 77.5M | 92.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 166.3M | 171.9M | 167.7M | 212.5M | 246.3M |
| Selling & Marketing Expense | 67.5M | 61.5M | 36.4M | 45.6M | 61.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 317.6M | 306.5M | 272.9M | 355.3M | 419.7M |
| Cost and Expenses | 1.1B | 1.1B | 1.0B | 1.2B | 1.4B |
| Operating Income (EBIT) | (9.6M) | 23.1M | (216.8M) | (936.4M) | 747.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (16.8M) | 16.0M | (231.6M) | (939.8M) | 728.8M |
| Income Tax Expense | (5.7M) | 2.5M | (5.1M) | (22.8M) | 366.3M |
| Bottom Line | |||||
| Net Income | (11.4M) | 13.4M | (226.5M) | (916.8M) | 362.6M |
| Earnings from Cont. Ops | (11.1M) | 13.6M | (226.5M) | (916.9M) | 362.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.4M) | 13.4M | (226.5M) | (916.8M) | 362.6M |
| Per Share | |||||
| Basic EPS | (CN¥0.02) | CN¥0.03 | (CN¥0.45) | (CN¥1.84) | CN¥0.73 |
| Diluted EPS | (CN¥0.02) | CN¥0.03 | (CN¥0.45) | (CN¥1.84) | CN¥0.73 |
| Revenue Per Share | CN¥2.51 | CN¥2.54 | CN¥1.93 | CN¥2.28 | CN¥2.67 |
| Shares | |||||
| Basic Shares Outstanding | 453.9M | 447.1M | 503.3M | 498.2M | 496.7M |
| Diluted Shares Outstanding | 453.9M | 447.1M | 503.3M | 498.2M | 496.7M |
| Profitability Metrics | |||||
| EBITDA | — | 121.3M | (109.5M) | (822.9M) | 913.3M |
| D&A | — | 98.2M | 107.3M | 113.5M | 165.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026